Prevention of Preterm Labor
Each year, more than one million babies die as a result of preterm delivery. This number has been static over the last forty years. Approximately 1 in 8 pregnancies deliver preterm and 25% of all pregnancies are at-risk.

NOVEL APPROACHES TO LABOR REGULATION

KynderMed possesses both near term clinical development opportunities, combined with additional product evolution plans and proprietary approaches to developing other first-in-class novel therapeutics.

KynderMed’s most advanced patented technology, a medical device called CERULEAN SLEEP, is currently undergoing a second round of human testing for the regulation of melatonin and prevention of contractions.

We are in the proof of concept stage.

In addition, KynderMed plans to subsequently launch a number of identified medical and usability enhancements.

KynderMed also plans to develop a proprietary, new pharmaceutical technology focused on improving the safety and comfort of labor induction.

SEE SCIENCE

Light as a Drug
Dr. James Olcese’s seminal research defined a synergistic relationship between melatonin and oxytocin, which promotes contractions. He further determined that the acute inhibition of melatonin lowers the incidence of nocturnal

CERULEAN SLEEP
KynderMed’s first initiative is a simple, non-invasive medical device that will safely and effectively enable at-risk women to avoid the onset of premature labor. The device uses a specific blue light spectrum to control the

KynderMed IN THE NEWS – FOX